San Diego, CA – Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not been determined.

 

Cowen and Company,  LLC and  BMO Capital Markets Corp. are  acting as joint book-running managers for the offering. Wedbush Securities Inc. is acting as a co-manager. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained from Cowen and Company, LLC,  c/o  Broadridge  Financial  Services,  Attention:  Prospectus  Department,  1155  Long  Island Avenue, Edgewood, New York 11717, Telephone: 631-274-2806, Fax: 631-254-7140; or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, New York, NY
10036, Telephone: 800-414-3627, Email: bmoprospectus@bmo.com.

 

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold,nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy,nor shall there be any sale of these securities in any  state  or  jurisdiction  in  which  such  offer,  solicitation  or  sale  would  be  unlawful,  prior  to registration or qualification under the securities laws of any such state

or jurisdiction.

 

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and evelopment of pharmacologic modulators of adult stem cells to treat orphan diseases, including certain  hematologic  malignancies,  lysosomal  storage disorders  and  muscular  dystrophies.  The Company  is  presently  advancing  its  lead  product  candidate,  ProHema,  a  pharmacologicallymodulated HSC therapeutic derived from umbilical cord blood, in Phase 2 clinical development for  hematologic  malignancies.  Fate  Therapeutics  is  also  advancing  its  Wnt7a  analogs  in preclinical  development  for  muscular  dystrophy.  Fate  Therapeutics  is  headquartered  in  San
Diego, CA. For more information, please visit www.fatetherapeutics.com.

 

Contact:
Paul Cox, Stern Investor Relations, Inc.
212.362.1200, paul@sternir.com